We thus assumed that by combining gene expression signatures obtained from pretreatment and on-treatment transcriptomic profiles with clinical data of patients, we could identify a novel promising biomarker to predict the response to anti-PD-1/PD-L1 monotherapy in NSCLC patients. Here, CD274 is linked to non-small cell lung carcinoma.